PUBLISHER: Grand View Research | PRODUCT CODE: 2067589
PUBLISHER: Grand View Research | PRODUCT CODE: 2067589
The global cardiovascular clinical trials market size was estimated at USD 12.2 billion in 2025 and is projected to reach USD 21.6 billion by 2033, growing at a CAGR of 7.7% from 2026 to 2033. The market is driven by the global burden of cardiovascular diseases (CVDs), growing demand for innovative therapies, and rising R&D investments by pharmaceutical and biotech companies.
Some other factors contributing to market growth are sedentary lifestyles, aging populations, smoking habits, stress, and unhealthy diets, which are significantly increasing the prevalence of cardiovascular diseases worldwide. Besides, rising cases of hypertension, heart failure, stroke, and coronary artery disease are driving demand for innovative therapies and medical devices. Thus, clinical research activities are expanding to develop advanced cardiovascular treatments that improve patient outcomes, reduce complications, and enhance survival rates.
The cardiovascular clinical trials industry is driven by the increasing global burden of cardiovascular diseases (CVDs) and a growing demand for innovative therapies. CVDs continue to be a leading cause of mortality worldwide, driving the need for effective drugs, medical devices, and preventive treatments. For instance, the American Heart Association Presidential Advisory mentioned that the burden of cardiovascular disease and associated risk factors is projected to rise substantially over the coming decades. By 2050, cardiovascular disease prevalence in the U.S. is anticipated to grow from approximately 11.3% to nearly 15% of the population, potentially impacting around 45 million adults.
In addition, stroke cases are expected to increase significantly, rising from nearly 10 million to close to 20 million adults. In addition, obesity, one of the primary contributors to cardiovascular disorders, is expected to expand from about 43% of the population to over 60%. These projections highlight the urgent need for stronger preventive healthcare strategies, improved risk-factor management, and greater investment in cardiometabolic disease prevention and treatment initiatives. This has led most pharmaceutical and biotechnology companies to boost their investments in research to develop advanced treatments for various cardiovascular conditions, including heart failure, hypertension, arrhythmias, ischemic heart disease, and lipid disorders. This expanding pipeline of therapeutics fuels the demand for specialized clinical trial services.
Global Cardiovascular Clinical Trials Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cardiovascular clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and region: